The product description

Rimonabant for obesity and smoking cessation in Acomplia CAS 168273-06-1

Quick details

Product name: Rimonabant

Alias: obesity; RIMONABANT; RIMONABANT(ACOMPLIA,SR141716); 5 - (4 - Chlorophenyl) - 1 - (2, 4 - dichlorophenyl) - 4 - methyl - N - piperidinopyrazole - 3 - carboxamide; 1 h - Pyrazole - 3 - formamide, 5 - (4 - chlorobenzene) - 1 - (2, 4 - dichlorobenzene) - 4 - methyl - N - 1 - piperidine base -; 5 - (4 - chlorobenzene) - 1 - (2, 4 - dichlorobenzene)) - 4 - methyl - N - 1 h - 1 - piperidine base - pyrazole - 3 - formamide; A 281; Sr 141716

CAS: 168273-06-1

MF: C22H21Cl3N4O

MW: 463.79

Assay 99%

appearance

Powder/weight loss Rimonabant is a selective antagonist

Product category: Weight loss; SR141716

Description of Rimonabant:

Rimonabant (Acomplia) is a potent cannabinoid receptor antagonist that reduces your food cravings, thereby helping you burn fat without undue emotional stress. It can't work alone, and it can't be combined with eating plans and regular exercise.

If your liver or kidney function is impaired, if you are younger than 18 years of age or are being treated for epilepsy, you should not start taking this medication without talking to your doctor.

Rimonabant has less information for younger people than 18 years old, so if you make this choice, you won't start taking the drug without first talking to your doctor. Your health care provider can start giving you a lower dose and then increase the dose to ensure you benefit from the treatment, with a normal recommended dose of 20 mg. You should take it at breakfast time.

advice

Quit smoking:

Rimonabant has been effective in supporting some smokers to quit. Studies have been conducted to determine the possible value of rimonabant in smoking cessation treatment.

The STRATUS (Rimonabant and Tobacco Use Study) program involved more than 6,000 subjects and was designed to explore two smoking-related therapies: direct use of rimonabant to help quit smoking.

Use rimonabant to help prevent weight gain in smokers. The primary results actually showed that rimonabant was effective for both uses.